Clay Siegall Leads the Way in Resarching Antibodies for Cancer Treatments

Seattle Genetics has been featured often in the news lately, with many articles detailing the biotech company’s ongoing efforts to expand into the larger pharmaceutical market. Seattle Genetics was founded in 1998 by Clay Siegall and has centered its research and development efforts into studying antibodies for cancer treatment strategies. Adcetris is one of the many drugs developed by Seattle Genetics and is used to treat Hodgkin lymphoma, which is a cancer that forms in the lymph nodes and can spread to other organs.

Seattle Genetics is looking to enlarge its horizons by moving into the marketing arena with its own drugs and also drugs from future acquired companies. Clay Siegall, the CEO, President and Chairman of Seattle Genetics, has stated that Seattle Genetics is an emerging oncology company and is poised to take its drugs into the global markets. Clay Siegall believes that four of the 11 drugs currently held by Seattle Genetics have a great possibility for immediate sales. One of these four drugs is number 33A and targets myeloid leukemia (AML), which currently has an unfavorable outlook.

Clay Siegall has a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland. Since acquiring his Ph.D., Clay Siegall has earned a long list of accomplishments. After beginning his career as a Senior Research Investigator with Bristol-Myers, Clay Siegall was promoted to Principal Scientist, then became a Staff Fellow and Biotechnology Fellow at the National Cancer Institute. After this appointment, Clay Siegall launched Seattle Genetics.

As the top executive leader and founder of Seattle Genetics, Clay Siegall has built Seattle Genetics into a leading developer of antibody-drug conjugates (ADCs) that are used to treat cancers. Currently, Seattle Genetics has license agreements with companies like GlaxoSmithKline, Genentech, Pfizer and AbbVie that has resulted in over $300 million being generated. Clay Siegall has worked diligently to raise capital for these developments and has garnered more than $675 million by public and private funding. Not just a leader in new drug therapies, Clay Siegall has published extensively on the research being conducted at Seattle Genetics. He has published over 70 scientific articles and also holds editorial board positions for three scientific journals.

No matter what direction Seattle Genetics ultimately takes in its quest to enlarge its footprint in the area of cancer drug development, it is certain that Clay Siegall will continue to research new therapies and share the results.

Comments are closed.